Lilly’s taltz and zepbound combination shows superior efficacy in psoriasis

Eli Lilly announced on Tuesday that their combination therapy using Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated superior efficacy in treating moderate to severe plaque psoriasis compared to either drug used alone during a Phase 3 clinical trial. The pharmaceutical giant revealed that patients receiving the dual treatment achieved a 90% improvement in skin clearance after 16 weeks, significantly outperforming the 68% and 72% response rates observed in groups receiving only Taltz or Zepbound, respectively. The trial, conducted across 85 medical centers in the United States and Europe, represents a potential breakthrough in autoimmune disease treatment by combining a biologic therapy with a dual incretin receptor agonist. 'These results validate our hypothesis that targeting multiple inflammatory pathways simultaneously can deliver transformative outcomes for patients living with psoriasis,' said David Ricks, Lilly's chairman and president, during a virtual investor conference. The company plans to seek FDA approval for the combination therapy by early 2025, which could generate an estimated $3 billion in additional annual revenue for the pharmaceutical giant as it expands its footprint in the competitive psoriasis treatment market.